As this exciting technology exploded in 2023, Pharm Exec was there to cover it all.
The Promise and Challenges of Generative AI in Healthcare
Pharma industry stakeholders must develop actionable roadmaps to prioritize the areas in which the use of generative artificial intelligence can create the greatest benefits.
Embracing AI: Q&A with Shalu Chadha
Accenture’s global life sciences technology lead discusses how the life sciences industry has embraced artificial intelligence.
AI and Drug 'Re-Innovation'
The application of artificial intelligence is steadily finding a home in the pharma industry, but these tools may have unprecedented potential in a more nascent niche along the life sciences continuum: drug development.
Harnessing AI for Pharma Sales
Artificial intelligence is steadily becoming a game changer for the pharma industry, particularly in commercialization activities, such as sales and marketing—and efforts to help highly sought treatments reach the right patients.
Data, AI, and the New Era of Field Teams: Q&A with Paul Shawah, executive vice president of commercial strategy at Veeva
Setting up a field team for the future necessitates equipping it with a toolbox of cutting-edge technological advancements. These tools enable the team to swiftly acquire essential, accurate information, as collectively advocated by biopharma organizations at Veeva's May 2023 Commercial Summit. Senior editor Fran Pollaro spoke with Paul Shawah, Veeva's executive vice president of commercial strategy, about the roles of data, ChatGPT, and AI in introducing new medicines to the market.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.